CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 46 enrolled
Drug / intervention
Temporarily holding the RAAS inhibitor [intervention] +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04508985
NCT04508985N/ACompleted
CompareCT.gov

Management of Renin-Angiotensin-Aldosterone System Blockade in Patients Admitted in Hospital With Confirmed Coronavirus Disease (COVID-19) Infection: The McGill RAAS-COVID-19 Randomized Controlled Trial

McGill University Health Centre/Research Institute of the McGill University Health Centre·interventional·Posted Aug 11, 2020·Updated Aug 7, 2023

In Brief

A clinical study evaluating Temporarily holding the RAAS inhibitor [intervention] and RAAS inhibitor [continued standard of care] for COVID-19 and Cardiovascular Diseases. Completed, enrolled 46 participants across 1 site.

Detailed Summary

Coronavirus disease (COVID-19) related pneumonia significantly impact patients with underlying cardiovascular (CV) conditions. Animal studies suggest that drugs commonly used to treated CV diseases may increase the ability of COVID-19 to infect cells. The RAAS-COVID-19 trial aims to assess whether temporarily holding these CV drugs in patients who are admitted with COVID-19, versus continuing them, in patients admitted with COVID-19 can impact short term outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Cardiovascular Diseases
CountriesCanada
CollaboratorsJewish General Hospital (Montreal, Quebec, Canada), Montreal General Hospital (Montreal, Quebec, Canada), Université de Lorraine, Centre d'Investigation Clinique- Plurithématique Inserm

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 11, 2020
Enrollment StartOct 1, 2020
Primary CompletionApr 1, 2021
Study CompletionApr 17, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.9 years ago

Interventions

Temporarily holding the RAAS inhibitor [intervention]other

Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.

RAAS inhibitor [continued standard of care]other

No intervention, Continuation RAAS inhibitor \[continued standard of care\].